(Q38570614)

English

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

scientific article published on 21 August 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 September 2017

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group (English)

1 reference

Europe PubMed Central

4 September 2017

1 reference

based on heuristic

inferred from title

chronic idiopathic myelofibrosis

1 reference

based on heuristic

inferred from title

9

object named as

A Tefferi

1 reference

Europe PubMed Central

4 September 2017

author name string

N M Kröger

1

1 reference

Europe PubMed Central

4 September 2017

J H Deeg

2

1 reference

Europe PubMed Central

4 September 2017

E Olavarria

3

1 reference

Europe PubMed Central

4 September 2017

D Niederwieser

4

1 reference

Europe PubMed Central

4 September 2017

A Bacigalupo

5

1 reference

Europe PubMed Central

4 September 2017

T Barbui

6

1 reference

Europe PubMed Central

4 September 2017

A Rambaldi

7

1 reference

Europe PubMed Central

4 September 2017

R Mesa

8

1 reference

Europe PubMed Central

4 September 2017

M Griesshammer

10

1 reference

Europe PubMed Central

4 September 2017

V Gupta

11

1 reference

Europe PubMed Central

4 September 2017

C Harrison

12

1 reference

Europe PubMed Central

4 September 2017

H Alchalby

13

1 reference

Europe PubMed Central

4 September 2017

A M Vannucchi

14

1 reference

Europe PubMed Central

4 September 2017

F Cervantes

15

1 reference

Europe PubMed Central

4 September 2017

M Robin

16

1 reference

Europe PubMed Central

4 September 2017

M Ditschkowski

17

1 reference

Europe PubMed Central

4 September 2017

V Fauble

18

1 reference

Europe PubMed Central

4 September 2017

D McLornan

19

1 reference

Europe PubMed Central

4 September 2017

K Ballen

20

1 reference

Europe PubMed Central

4 September 2017

U R Popat

21

1 reference

Europe PubMed Central

4 September 2017

F Passamonti

22

1 reference

Europe PubMed Central

4 September 2017

D Rondelli

23

1 reference

Europe PubMed Central

4 September 2017

G Barosi

24

1 reference

Europe PubMed Central

4 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

21 August 2015

1 reference

Europe PubMed Central

4 September 2017

1 reference

Europe PubMed Central

4 September 2017

29

1 reference

Europe PubMed Central

4 September 2017

11

1 reference

Europe PubMed Central

4 September 2017

2126-2133

1 reference

Europe PubMed Central

4 September 2017

https://scigraph.springernature.com/pub.10.1038/leu.2015.233

0 references

MPN-associated myelofibrosis (MPN-MF).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

The Delphi technique: a methodological discussion

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Leukemia risk models in primary myelofibrosis: an International Working Group study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Mutations and prognosis in primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Somatic mutations of calreticulin in myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party o

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Outcome of transplantation for myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Effects of spleen status on early outcomes after hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Peripheral-blood stem cells versus bone marrow from unrelated donors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic hepatic impairment: analysis of the literature and recommendations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Guideline for the diagnosis and management of myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.233

21 January 2018

Allogeneic bone marrow transplantation for primary myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Resea

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Splenectomy and hemopoietic stem cell transplantation for myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced transfusion requirements in a splenectomized patient undergoing bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of allogeneic stem cell transplantation in patients with myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic hematopoietic stem cell transplantation for myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stem cell transplantation for myelofibrosis: a report from two Canadian centers

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review

1 reference

https://pubmed.ncbi.nlm.nih.gov/26293647

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2015.233

1 reference

Europe PubMed Central

4 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

4 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38570614&oldid=1767461327"